Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer

Oncologist

Volumn 20, Issue 9, 2015, Pages 1001-1010

  Guarneri, Valentina ^a,b   Dieci, Maria Vittoria ^a   Frassoldati, Antonio ^c   Maiorana, Antonino ^d   Ficarra, Guido ^d   Bettelli, Stefania ^d   Tagliafico, Enrico ^e   Bicciato, Silvio ^e   Generali, Daniele Giulio ^f   Cagossi, Katia ^g   Bisagni, Giancarlo ^h   Sarti, Samanta ⁱ   Musolino, Antonino ^j   Ellis, Catherine ^k   Crescenzo, Rocco ^k   Conte, PierFranco ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f CREMONA HOSPITAL   (Italy)

^g Ramazzini Hospital Carpi   (Italy)

^h Department of Medical Oncology Azienda Ospedaliera ASMN IRCCS Reggio Emilia   (Italy)

ⁱ DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^j University Hospital Parma   (Italy)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

Breast neoplasms; Gene expression profiling; Molecular targeted therapy; Neoadjuvant therapy; p95 HER2; PIK3CA

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; LAPATINIB; PACLITAXEL; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUNEL ASSAY; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NEOADJUVANT THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MUTATION; NEOADJUVANT THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84940646917     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0138     Document Type: Article

References (31)

1. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone re- ceptor status and other factors. J Clin Oncol 2006;24: 1037-1044
2. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014;384:164-172
3. Scaltriti M, Rojo F, Ocaña A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99: 628-638
4. Arribas J, Baselga J, Pedersen K et al. p95HER2 and breast cancer. Cancer Res 2011;71: 1515-1519
5. Sperinde J, Jin X, Banerjee J et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010;16: 4226-4235.
6. Duchnowska R, Sperinde J, Chenna A et al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: Independent validation of the p95HER2 clinical cutoff. Clin Cancer Res 2014;20:2805-2813
7. Amzel LM, Huang CH, Mandelker D et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-669.
8. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177:1647-1656.
9. Dave B, Migliaccio I, Gutierrez MC et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29: 166-173.
10. Razis E, Bobos M, Kotoula V et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011;128: 447-456
11. Baselga J, Cort és J, Im SA et al. Biomarker analyses in CLEOPATRA: A phase III, placebocontrolled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line meta- static breast cancer. J Clin Oncol 2014;32: 3753-3761.
12. Xu B, Guan Z, Shen Z et al. Association of phosphatase and tensin homolog low and phos-phatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Breast Cancer Res 2014;16:405
13. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-1995.
14. Bicciato S, Spinelli R, Zampieri M et al. A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets. Nucleic Acids Res 2009;37:5057-5070.
15. Ferrari F, Solari A, Battaglia C et al. PREDA: An R-package to identify regional variations in genomic data. Bioinformatics 2011;27: 2446-2447.
16. McCullough AE, Dell’orto P, Reinholz MM et al. Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/ NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 2014;143:485-492.
17. Perez EA, Press MF, Dueck AC et al. Immuno-histochemistry and fluorescence in situ hybridiza- tion assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013; 138:99-108.
18. Majewski IJ, Nuciforo P, Mittempergher L et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted ther- apies in breast cancer. J Clin Oncol 2015;33: 1334-1339.
19. Loibl S, von Minckwitz G, Schneeweiss A et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014;32:3212-3220.
20. Guarneri V, Dieci MV, Carbognin L et al. Activity of neoadjuvant lapatinib (L) plus trastuzumab (T) for early breast cancer (EBC) according to PIK3CA mutations: Pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trials [abstract 254O]. Presented at: European Society of Medical Oncology meeting; September 26-30, 2014, Madrid, Spain
21. Loibl S, Majewski I, Guarneri V. PIK3CA mutation correlates with pathological complete S response in primary HER2-positive breast cancercombined analysis of 967 patients from three prospective clinical trials. J Clin Oncol 2015;33 (suppl):511a
22. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12: 395-402.
23. Loibl S, Darb-Esfahani S, Klimowicz A et al. PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer [abstract PD5-7]. Presented at: San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX
24. Loibl S, Bruey J, von Minckwitz G et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 2011;29(suppl):530a
25. Scaltriti M, Nuciforo P, Bradbury I et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015;21:569-576.
26. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumabbased neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381-7388.
27. Guarneri V, Dieci MV, Barbieri E et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 2013;24:2990-2994.
28. Jones RL, Salter J, A’Hern R et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116:53-68.
29. Guarneri V, Piacentini F, Ficarra G et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009;20: 1193-1198.
30. Tabchy A, Valero V, Vidaurre T et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010;16:5351-5361.
31. Mellissa Hicks, Erin R. Macrae, Mahmoud Abdel-Rasoul et al. Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A MetaAnalysis of Randomized Prospective Clinical Trials. The Oncologist 2015;20:337-343